Performing a minimally invasive staging laparoscopy on patients with newly diagnosed pancreatic cancer may help determine the stage and identify cancer metastases early, according to a novel study published by Gudmundsdottir et al in the Journal of the American College of Surgeons. The new findings ...
Investigators have called into question the health benefit of extended surveillance for patients whose pancreatic cysts have not changed size for at least 5 years and had no worrisome features, according to a new study published by Chhoda et al in Clinical Gastroenterology and Hepatology....
The vast majority of cancer survivors may rely on primary care physicians for follow-up treatments, especially in rural areas, according to a new study published by Becevic et al in the Journal of Cancer Education. Background Patients often depend on their primary care physicians to help them...
Physicians may be able to personalize dosing intervals and consequently improve patient outcomes by monitoring early-response biomarkers in patients with prostate cancer who are undergoing treatment with lutetium (Lu)-177–PSMA, according to new findings presented by Emmett et al at the Society of...
In the Dutch Colorectal Cancer Group phase III CAIRO5 study reported in The Lancet Oncology, Bond et al investigated first-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases. The researchers found that FOLFOXIRI (leucovorin, fluorouracil,...
As reported in the Journal of Clinical Oncology by O’Donnell et al, findings in a cohort of the phase Ib/II EV-103/KEYNOTE-869 study showed durable responses with first-line enfortumab vedotin-ejfv plus pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial...
In a prospective study (SYMPLIFY) reported in The Lancet Oncology, Nicholson et al found that a circulating tumor DNA methylation-based multicancer early detection diagnostic test showed promise in predicting a diagnosis of cancer in symptomatic patients referred from primary care for...
In a Chinese phase III trial reported in the Journal of Clinical Oncology, Ling et al found that conditioning with busulfan/fludarabine resulted in reduced transplantation-related mortality vs busulfan/cyclophosphamide in patients with acute myeloid leukemia (AML) undergoing human leukocyte antigen ...
On June 29, the U.S. Supreme Court ruled to end race-conscious college admissions. In reaction to the Court’s ruling, and its potential effect on reversing progress toward increasing diversity in the nation’s physician workforce, ASCO released the following statement from Chief Executive Officer...
In the phase III BMT CTN 1703 trial reported in The New England Journal of Medicine, Bolaños‑Meade et al found that posttransplantation cyclophosphamide-based graft-vs-host disease (GVHD) prophylaxis improved GVHD-free, relapse-free survival vs standard prophylaxis in patients with hematologic...
In a phase I study (TROPION-PanTumor01) reported in the Journal of Clinical Oncology, Shimizu et al described outcomes with the trophoblast cell-surface antigen 2 (TROP-2)-directed antibody-drug conjugate datopotamab deruxtecan at the dose selected for further development in patients with advanced...
The positron-emission tomography (PET) tracer zirconium (Zr)-89–DFO-girentuximab may accurately identify patients with clear cell renal cell carcinoma and differentiate the disease from other types of renal tumors, according to findings presented by Calais et al at the Society of Nuclear Medicine...
Researchers have identified a new potential therapeutic target—the cell-surface tumor antigen CUB domain–containing protein 1 (CDCP1)—for patients with all subtypes of metastatic bladder cancer, according to findings presented by Chopra et al at the Society of Nuclear Medicine & Molecular...
Researchers have created the world’s largest and most comprehensive atlas of normal breast tissue—the Human Breast Cell Atlas—which may provide an unprecedented understanding of mammary biology and help identify therapeutic targets for diseases such as breast cancer, according to a recent study...
In the phase III NRG Oncology/RTOG 0232 trial reported in the Journal of Clinical Oncology, Jeff M. Michalski, MD, MBA, FASTRO, and colleagues found no significant benefit in 5-year freedom from disease progression with the addition of external-beam radiation therapy (EBRT) to brachytherapy in...
Patients with polycystic ovary syndrome may not have a higher risk of ovarian cancer than those without the condition; however, postmenopausal patients with polycystic ovary syndrome may have twofold the risk of developing ovarian cancer, according to recent findings presented by Frandsen et al at...
Female survivors treated for Hodgkin lymphoma may face declining fertility at a younger age, according to recent findings presented by Drechsel et al at the European Society of Human Reproduction and Embryology (ESHRE) 2023 Annual Meeting (Abstract O-083). The new research also suggested that the...
Researchers have identified seven potential risk factors for early-onset colorectal cancer in male patients and developed a novel risk evaluation model, according to a recent study published by Imperiale et al in Cancer Prevention Research. The findings may help 45- to 49-year-old patients accept...
As reported in the Journal of Clinical Oncology by Caroline Robert, MD, PhD, and colleagues, the 7-year follow-up of the phase III KEYNOTE-006 trial has shown a continued overall survival benefit with pembrolizumab vs ipilimumab in patients with advanced melanoma. The primary analysis of the trial...
In an analysis reported in the Journal of Clinical Oncology, Martin F. Kaiser, MD, and colleagues found that daratumumab plus low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd) used as induction and extended consolidation therapy in newly diagnosed patients with...
In the phase III FRESCO-2 trial reported in The Lancet, Dasari et al found that the VEGFR-1,2,3 inhibitor fruquintinib prolonged survival vs placebo in patients with refractory metastatic colorectal cancer. Study Details In the double-blind trial, 691 patients from sites in 14 countries were...
In the phase II AMEERA-3 trial reported in the Journal of Clinical Oncology, Sara M. Tolaney, MD, MPH, and colleagues found that the selective estrogen receptor degrader amcenestrant did not improve progression-free survival vs physician’s choice of endocrine therapy in patients with estrogen...
In the CANVAS study, reported in JAMA, Deb Schrag, MD, FASCO, MPH, and colleagues found that use of direct oral anticoagulants was noninferior to low–molecular-weight heparin in preventing recurrent venous thromboembolism (VTE) in patients with cancer. Study Details In the open-label trial, 671...
A report from the German OCUM study published by Ruppert et al in the Journal of Clinical Oncology details long-term locoregional recurrence outcomes with risk-adapted neoadjuvant chemoradiotherapy plus total mesorectal excision and total mesorectal excision alone in patients with rectal cancer....
About 50% of LGBTQ+ patients and survivors of cancer may be concerned about facing discrimination in a health-care setting, according to a new survey from the American Cancer Society Cancer Action Network (ACS CAN). The new findings demonstrated that these concerns and experiences with...
The combination of curettage and cryosurgery may be a safe and effective treatment method for patients with basal cell carcinoma, according to a novel study published by Backman et al in the Journal of the American Academy of Dermatology. Background The incidence of skin cancer is continuing to...
On June 26, 2023, the Biden-Harris Administration awarded $50 million in the launch of the Persistent Poverty Initiative—a program designed to alleviate the cumulative effects of persistent poverty on cancer outcomes by increasing research capacity, fostering cancer prevention research, and...
Iopromide-300 and -370 (Ultravist), an iodine-based contrast agent, has been approved by the U.S. Food and Drug Administration (FDA) for contrast-enhanced mammography—making it the only contrast agent approved for this indication. The product can be used to visualize known or suspected lesions of...
In the phase II DESTINY-Gastric02 trial reported in The Lancet Oncology, Eric Van Cutsem, MD, PhD, and colleagues found that fam-trastuzumab deruxtecan-nxki (T-DXd) was active in patients with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a...
Interim results of a phase II study (EQOL-MDS) reported in the Journal of Clinical Oncology by Oliva et al showed that eltrombopag, an orally bioavailable small molecule acting as a thrombopoietin receptor agonist, significantly increased the rate of platelet response vs placebo in patients with...
In an analysis reported in the Journal of Clinical Oncology, Ariffin et al found noninferior event-free survival with an anthracycline-free vs anthracycline-containing regimen among children with favorable-risk B-cell precursor acute lymphocytic leukemia (ALL) enrolled in two Malaysia-Singapore ALL ...
Investigators have found that artificial intelligence (AI) language models like OpenAI’s ChatGPT may accurately identify appropriate imaging tests for breast cancer screenings and breast pain, according to a recent study published by Rao et al in the Journal of the American College of Radiology....
Women of African descent may have an elevated risk of being diagnosed with advanced endometrial cancer and developing aggressive tumors compared with White women, according to a recent study published by Medina et al in Cancer. Background Endometrial cancer is classified as endometrioid or the more ...
Children of parents with a history of cancer are more likely to face housing and food insecurity and delayed medical care due to a lack of transportation compared to children without a parental history of cancer, according to a study published by Zheng et al in JAMA Network Open. Among these...
As reported in the Journal of Clinical Oncology by Emmanuel S. Antonarakis, MD, and colleagues, the phase III KEYLYNK-010 trial has shown no improvement in survival outcomes with pembrolizumab/olaparib vs a next-generation hormonal agent (abiraterone or enzalutamide) in previously treated patients...
In an analysis from the Childhood Cancer Survivor Study (CCSS) reported in the Journal of Clinical Oncology, Bates et al identified relationships among radiation therapy doses, cardiac substructures, and risk of late-onset cardiac disease in survivors of childhood cancer. Study Details The analysis ...
In an updated individual patient data network meta-analysis reported in The Lancet Oncology, Petit et al found that the treatment approach with the highest overall survival benefit among patients with nonmetastatic nasopharyngeal carcinoma treated with radiotherapy was induction chemotherapy with...
A combination of pretherapy imaging and dosimetry may help patients with refractory differentiated thyroid cancer obtain the maximum benefit from radioactive iodine treatments following redifferentiation therapy, according to a novel study published by Taprogge et al in The Journal of Nuclear...
A genetic marker involving the EGFR and ERBB2 genes may be predictive of which patients with hepatocellular carcinoma are most likely to develop resistance to lenvatinib, according to a study published by Lim et al in Gastroenterology. The new findings could help researchers develop alternative...
Yoshie Umemura, MD, was recently appointed as Chief Medical Officer of the Ivy Brain Tumor Center and Chief of Neuro-Oncology and the William and Joan Shapiro Chair of Neuro-Oncology at Barrow Neurological Institute. Dr. Umemura plans to build on the Ivy Center’s clinical trials program and...
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus on ...
Cervical cancer is a serious problem in many low- and middle-income countries such as the African country of Rwanda. Although the cervical cancer rate in Rwanda remains more than twice the U.S. rate, there has been improvement in recent years that cancer research organizations can learn from to...
Delays in cancer screening during the COVID-19 pandemic will likely cause a significant increase in cancer cases that could have been caught earlier with screening. These cases may now be diagnosed at later stages, placing an increased burden on an already-strained health-care system, according to...
New research involving people living with HIV treated with immune checkpoint inhibitors has provided valuable insights into the safety and efficacy of immunotherapy in this historically excluded population, according to data published in the Journal of Clinical Oncology.1 The real-world data...
The formal discussant of the phase II SWOG S1512 trial was Zeynep Eroglu, MD, of the Department of Cutaneous Oncology at the Moffitt Cancer Center in Tampa, Florida. She congratulated Dr. Kendra and her coauthors for conducting a study in such a rare tumor. “I think we can say desmoplastic melanoma ...
The immune checkpoint inhibitor pembrolizumab achieved high response rates in patients with unresectable metastatic desmoplastic melanoma, a rare invasive tumor type, according to the results of the phase II SWOG S1512 trial presented at the 2023 American Association for Cancer Research (AACR)...
Commenting on this study on clinical genomic profiling for colorectal cancer, Lisa Newman, MD, MPH, FACS, FASCO, Chief of the Section of Breast Surgery and leader of the Multidisciplinary Breast Oncology Programs at Weill Cornell Medicine and NewYork-Presbyterian, commended the authors for...
Black individuals have a higher incidence of colorectal cancer than White individuals, and their outcomes are worse. Undoubtedly, reasons for this are multifaceted, but the disparity in outcomes may be partly explained by genomic differences, documented in a large retrospective study presented at...
Testing for the emergence of ESR1 mutations should be routine at disease recurrence or progression for patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer whose disease is being managed with endocrine therapy, according to an ASCO guideline rapid recommendation...
ASCO has issued new clinical guidance for treating patients with gastrointestinal cancers amid a nationwide shortage of carboplatin and cisplatin. The two chemotherapy agents, in extremely short supply, are essential to treating an array of gastrointestinal cancers—such as esophageal, pancreatic,...